MARKET

HRTX

HRTX

Heron Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.19
+0.79
+4.82%
After Hours: 17.50 +0.31 +1.80% 18:52 07/15 EDT
OPEN
16.84
PREV CLOSE
16.40
HIGH
17.23
LOW
16.72
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
26.81
52 WEEK LOW
9.60
MARKET CAP
1.56B
P/E (TTM)
-7.5677
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HRTX stock price target is 31.40 with a high estimate of 70.00 and a low estimate of 19.00.

EPS

HRTX News

More
Heron Therapeutics readies mid-stage study of aprepitant for COVID-19
Heron Therapeutics (HRTX +3.3%) perks up on average volume in apparent response to the posting in ClinicalTrials.gov of a Phase 2 clinical trial, GUARDS-1,
seekingalpha · 1d ago
Heron Therapeutics (HRTX) in Focus: Stock Moves 9% Higher
Zacks · 07/03 03:38
Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst
SmarterAnalyst · 07/01 19:26
Heron Therapeutics: The Play Now
Seeking Alpha - Article · 06/30 17:41
Kiniksa's Heart Drug, And Other News: The Good, Bad, And Ugly Of Biopharma
Seeking Alpha - Article · 06/30 17:14
Heron's Pain Management Drug Gets Complete Response Letter
Zacks · 06/30 16:15
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 06/30 11:41
ICPT, WKHS, HRTX and BLNK among midday movers
Seeking Alpha - Article · 06/29 16:41

Industry

Biotechnology & Medical Research
+1.30%
Pharmaceuticals & Medical Research
+1.59%

Hot Stocks

Symbol
Price
%Change

About HRTX

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
More

Webull offers kinds of Heron Therapeutics Inc stock information, including NASDAQ:HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.